Recent Updates — ALNY

Alnylam Pharmaceuticals reported third-quarter 2026 total revenues of $1,458 million, a 17% increase year-over-year, driven by a 52% surge in net product revenues to $1,292 million led by the TTR franchise. GAAP net income reached $2,167 million ($15.72 diluted EPS), significantly higher than the prior year's $293 million, primarily due to a $1.9 billion benefit from the release of valuation allowances on deferred tax assets. The company reiterated its full-year 2026 total net product revenue guidance of $4.7 billion to $5.1 billion and announced an expansion of the TRITON-CM Phase 3 study enrollment for nucresiran to 2,250 patients. Alnylam Pharmaceuticals is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics.

Alnylam Pharmaceuticals reported second quarter 2026 financial results on July 30, 2026, achieving total revenues of $1.29 billion and GAAP net income of $164 million (GAAP EPS: $1.21). Total net product revenues grew 74% year-over-year to $1.17 billion, driven primarily by a 106% increase in AMVUTTRA sales to $1.01 billion and an 11% rise in Rare disease products to $142 million. The company lowered its full-year 2026 total TTR net product revenue guidance range from $4.4–$4.7 billion to $4.2–$4.5 billion, citing normalized second-line demand growth in the U.S. ATTR-CM market after initial pent-up demand was satisfied. Additionally, Alnylam initiated Phase 2 trials for ALN-6400 and mivelsiran, appointed Benjamin Franklin Cravatt III to its Board, and entered an exclusive commercial agreement with BeOne Medicines for AMVUTTRA in China. The company operates as a biopharmaceutical firm pioneering RNA interference (RNAi) therapeutics.